Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. The company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cord, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare

40 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Biotech Company 100% Focused On Advancing New Therapies For Childhood Cancer A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ON DEMAND CYTOKINE Company Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response. ON DEMAND CYTOKINE, CYTOKINE DRUG, IMMUNO-ONCOLOGY, and TARGETED ONCOLOGY

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the next generation bacterial cancer therapy Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to discover, develop and deliver next generation cancer therapies. G1 Therapeutics, Inc. is a wholly owned subsidiary of Pharmacosmos. Cancer / Oncology, Drug Discovery and Development, and Biotechnology

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

we aim to develop new therapeutics for the treatment of brain disorders based on human cerebral organoids a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of …

21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen was founded by five leading-edge scientists: K. Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D., Ph.D. from Stanford University; Claudia Janda, Ph.D. from the Princess Maxima Center for Pediatric Oncology; and Hans Clevers, M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen’s technology and approach to therapeutic development. The …

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First in class small molecules pushing cancer cells to burn out BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics

Next generation bioproduction platform Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

167 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2013-2023 In a context where the rate of cancer treatment failure is still unacceptably high, our mission is to provide decision aids to oncologists. We believe that profiling is key to predicting treatment toxicity to patients and effectiveness on tumors. Over a decade of research by the French Atomic Energy Commission (CEA) on the impact of radiations on DNA has resulted in a deep understanding of the essential DNA repair mechanisms. More recently, a set of innovative biomarkers was developed that provides a complete functional signature of these mechanisms, the premise to powerful tools for personalized treatment of cancer. http://www.lxrepair.com …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

137 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

207 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Swalife Biotech, we are at the forefront of developing next-generation therapies for cancer and chronic diseases. Our research is rooted in the discovery of five novel bioactive alkaloids from plants, aimed at synthesizing compounds that target key mechanisms in skin and breast cancer. We leverage cutting-edge technologies such as network pharmacology and AI to enhance our understanding and development of drug therapies. Our alkaloids have shown promising results in inhibiting the DNA Damage Response (DDR) pathway, crucial in preventing drug resistance and cancer cell survival. Our innovative approach not only targets cancer but also extends to managing chronic diseases, …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Bio sourced materials

Cell Therapy for All TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a …

52 similar entities Tags: FrenchTech120 FrenchTech2030 Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the power of NIK to transform the future of cancer and autoimmune disease treatment Nikaia Pharmaceuticals, an innovative company dedicated to the discovery and development of cutting-edge therapeutic solutions to improve patients' lives. 🔬💊 Our mission is to push the boundaries of science to deliver novel and effective treatments, focusing on the NIK protein (NF-κB-inducing kinase) and developing molecules capable of blocking its action.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Kuur is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of T cells, called natural killer T cells (NKT cells) and innovative chimeric antigen receptor (CAR) construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors. Immunotherapy, Cancer, Oncology, T cells, TCR, CAR, CAR-NKT, clinical trial, NKT Cells, celltherapy, and lifesciences

76 similar entities Type: SMB Activities: biotech deeptech transporttech Technologies: Synthetic Biology

Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology

New view for cancer Therapeutic Sirius Neosight is an innovative technological breakdown company which aims to become a key player in the detection of subclashed neo-cancers, relapses and therapeutic monitoring of patients thus offering a new look to doctors on the therapeutic efficiency implemented. Sirius Neosight operates a patented from a patented rupture technology from a consortium of academic laboratory experts in the field.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nano Life Sciences Cementic, founded in 2016, is a pioneering biotech startup with bases in Paris, France, and Palo Alto, USA. Specializing in cutting-edge nano-biotechnology solutions, our focus is on revolutionizing healthcare through innovative applications in dental care, orthopedics, and stem cell research. We leverage new paradigms to address complex health challenges, advancing global health from our dual locations. Medtech, Biotech, Dental, Orthopedics, Nanotechnolgies, Stem cells , and Liposomes

71 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

520 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

294 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dyameo is a research company & amp; Development in the field of medical devices which designs aid probes for the diagnosis of in-vivo cancer cells. This medical device, makes it possible to answer the question: "Are these cells cancerous?", And that in a simple, clear and instant manner. This rupture solution proposes to discriminate cancer cells at an early stage, during endoscopic examinations. Medical devices, medtech, and help with in-vivo cancer diantics

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bone targeted delivery concept Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug www.atlanthera.com Watch our concept in video > https://youtu.be/m3BBWguO6hs Durg discovery, Bone-targeted drug delivery, Bone cancer, and Bone metastases

43 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low …

48 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering DARPin Therapeutics for Patients Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA. DARPins, Oncology, Immuno-Oncology, Radiopharmaceuticals, …

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative biotech company developing next generation of cell culture systems designed to revolutionize biomanufacturing Cellevate develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3dTM - with the potential to revolutionize upstream bioprocessing from R&D to commercial manufacturing. Our latest product line in development – Cellevat3dTM carriers – with a commercial launch planned for 2024, provides extracellular-like environments with exceptional surface areas for adherent cell cultures. Initial results show tremendous potential to increase yields, minimize risk and reduce costs in development and manufacturing. We offer a range of products based on our versatile and easily functionalized platform …

58 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Redefining Synthetic Lethality beyond HRD Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion. drug discovery, precision oncology, and biotechnology

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

662 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We're committed to translating our ground-breaking science into genomic medicines that transform patients’ lives. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. To learn more about Sangamo, visit the our website at www.sangamo.com. Biotechnology, Genome Editing, Gene Therapy, MPS II, MPS I, Hemophilia A, Hemophilia B, Beta Thalassemia, Gene Therapy, Fabry, …

40 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a biotech start-up which deals with the development of stem cell-based medicinal products for veterinary use. Currently, our main goal is to implement a biopharmaceuticals based on allogenic stem cells. The medicines will be primarily to serve the treatment of accompanying animals. The new product candidates will become a milestone in the field of stem cell-based biopharmaceuticals for veterinary use. As one of the first such Europe-based company, Bioceltix product intends to go through the full registration path to a marketed drugs devised …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We see the future in cells CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have …

71 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

438 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The surfaceome company. DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK

119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ahead of the Curve Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease. Website: www.ornatx.com

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell therapy Acceleration and Innovation: Rethinking cell & gene therapy By Institut Curie CellAction (Cell therapy Acceleration and Innovation) is the cell and gene therapy platform of the Paris-Saclay Cancer Cluster (PSCC) at Institut Curie. A first in France, CellAction enables collaborative projects to be launched with industrial partners on a national and international scale. The aim is to accelerate the development of optimized cell and gene therapies. CellAction is founded on the centralization of key expertise required for the drug development process: - Institut Curie's highly qualified medical-scientific teams - Cutting-edge technologies for in vitro and in vivo testing …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

TissueGen is a developer of next generation drug delivery technologies. TissueGen solves for unmet needs through the development of transformative drug delivery technologies that reduce treatment burden and improve clinical outcomes. We create life changing treatment modalities for patients and their caregivers, treating both acute and chronic conditions.

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Research center & amp; Health development Bionoveo offers project leaders, industrial or academic, biological, technical and methodological skills and resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes.

283 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

131 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

3D cell shape + AI to bring the right therapies to the right patients sooner Sentinal4D is an AI-powered cancer drug discovery and development company, with close ties to the Institute of Cancer Research. Sentinal4D represents a collaboration of physics, biology and artificial intelligence to drive novel cancer therapy candidates with a high probability of clinical success. Artificial Intelligence, Computer Vision, Systems Biology, and Drug Discovery

108 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

An evolution in cell line engineering. High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

171 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Giving Life to Science PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

279 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Curing blindness with regenerative cell therapies. StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.

30 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A new class of cancer therapies using RNA-guided nucleases for specific cell depletion Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's …

32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines. Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal …

18 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

131 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

StemInsure®: Your Younger Cells For Life® Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy. We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Treating the untreatable BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing the state-of-the-art in nature-based healthcare solutions Adamas Biotech is a clinical stage company pioneering the development of nutraceutical-based prophylactic and therapeutic solutions for a range of clinical and wellness indications. The company is specialized in the development of bioactive molecules derived from botanicals, in particular, green tea catechins. Its initial pipeline is based on 100% natural formulations of green tea purified compounds, which are under development for use in cancer prevention, anti-aging, wound care and sports medicine.

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Helping cancer patients to get the right drugs Cancer is a disease with millions of variations where even the most effective current treatment protocols will not work for many patients. We at AIDA believe that modern high-performance computing and machine learning combined with cutting-edge gene reading tools can fast forward personalized cancer therapy and improve treatment options for cancer patients.

37 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning

We're on a mission to cure blindness with our transformational platform of advanced therapies Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing precision to the power of biologics with pioneering use of synthetic nanoclays for regenerative medicine. Renovos Biologics Ltd. (Renovos) is a biotech/medtech company focussed on the development of its patented synthetic nanoclay, RENOVITE®, as a drug delivery platform for regenerative medicine and beyond. Regenerative Medicine, Biomaterials, Drug Delivery, Medical Devices, Pharmaceuticals, Stem Cells, Orthopaedics, and Biotechnology

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active …

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting synthetic lethality in cancer Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Eisbach will beat cancer at its own game.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Light Activated Technologies for treating cancers and rare diseases Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

299 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

World leaders in iPSC technology supporting the next generation of advanced models for drug discovery We provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, we support the pursuit of more human-relevant in vitro models to develop better, safer therapies. We have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Our industry-leading iPSC capabilities support the pursuit …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing next generation DDR targeting therapies Nodus oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area. Founded by Cumulus Oncology and in partnership with the Lead discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations Oncology

23 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing deuterated BEST in CLASS MET kinase Inhibitor DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2. Drug Development, Deuterated small molecules, and MET kinase inhibitor

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Platform to engineer cancer killing viruses using synthetic biology. Humane Genomics is developing a platform to engineer cancer killing viruses with unprecedented specificity and efficiency. Our first indication is liver cancer. We are based in New York City and backed by amazing investors. (YC S21)

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

398 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Revolutionary intracellular screening platform enables a new generation of first-in-class drugs. Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

215 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology